Koers Cellectar Biosciences Inc Nasdaq
Aandelen
US15117F3029
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | 44,27 mln. 40,74 mln. | Marktkapitalisatie | 118 mln. 109 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -65 mln. -59,81 mln. | Nettowinst (verlies) 2025 * | -32 mln. -29,45 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,67 x |
K/w-verhouding 2024 * |
-1,75
x | K/w-verhouding 2025 * |
-4,36
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,91% |
Recentste transcriptie over Cellectar Biosciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
James Caruso
CEO | Chief Executive Officer | 65 | 15-06-15 |
Chad Kolean
DFI | Director of Finance/CFO | 59 | 28-05-14 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 07-04-17 |
Douglas Swirsky
CHM | Chairman | 54 | 07-04-17 |
John Neis
BRD | Director/Board Member | 68 | 01-02-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+32,09% | 693 mld. | |
+29,39% | 584 mld. | |
-1,34% | 372 mld. | |
+20,34% | 332 mld. | |
+7,39% | 294 mld. | |
+14,25% | 239 mld. | |
-3,03% | 211 mld. | |
+10,02% | 210 mld. | |
+8,49% | 168 mld. |